Antimicrobial Resistance: The Silent Pandemic and the Power Struggles Behind It

The London School of Public Health – Public health without border series

Ever wondered how the global pharmaceutical industry influences childhood immunisation programmes? Explore the complex relationship between Big Pharma, vaccine policies, and public health outcomes. This blog dives into the controversies, ethics, and data that shape the decisions behind every childhood jab — and how studying a BSc in Public Health can equip you to be part of the solution.

Antimicrobial resistance (AMR) stands as one of the gravest threats to global health in the 21st century. The World Health Organization warns that without urgent action, AMR could cause 10 million deaths annually by 2050 and reverse decades of medical progress (WHO, 2024). While scientific discourse often focuses on bacterial evolution and clinical misuse, an equally critical, yet underexamined, dimension lies in the entangled politics of global pharmaceutical power and governance.

Big Pharma: Corporate Profiteering at the Expense of Public Health

The multinational pharmaceutical industry colloquially known as Big Pharma is a dominant force in global health. Yet, their role in AMR is marked by paradox and controversy. These corporations have flooded markets, particularly in low- and middle-income countries (LMICs), with antibiotics that are often misused due to weak regulation and aggressive marketing strategies (Belkhir and Seguin, 2018). This corporate profiteering thrives in regulatory vacuums, where the interests of profit frequently eclipse the imperatives of public health.

In LMICs, pharmaceutical companies often exploit governance weaknesses to push broad-spectrum antibiotics over the counter without prescriptions (Okeke et al., 2021). This facilitates rampant misuse and accelerates resistance, disproportionately harming vulnerable populations. Compounding this, some companies continue manufacturing practices that pollute environments with antibiotic residues, creating “resistance hotspots” with global repercussions (Larsson et al., 2018).

Meanwhile, despite the urgent need for new drugs, Big Pharma has systematically retreated from antibiotic innovation due to low profitability, favouring chronic disease and lifestyle medications instead (Renwick, Brogan and Mossialos, 2016). This market failure persists despite widespread calls for incentivizing novel antibiotic development.

The Fentanyl Crisis: A Stark Cautionary Tale

The dark underbelly of pharmaceutical influence is glaringly illustrated by the opioid epidemic in the United States. Companies such as Purdue Pharma aggressively marketed fentanyl and other opioids as safe, underplaying addiction risks, which contributed to over 70,000 overdose deaths per year (CDC, 2023; Van Zee, 2009). This epidemic exposed the catastrophic consequences of corporate misinformation and regulatory capture lessons urgently relevant as these corporations expand into LMIC markets with similarly powerful drugs.

Regulatory crackdowns in the US and Europe have prompted pharmaceutical giants to shift focus toward LMICs, where over-the-counter availability and lax oversight create fertile ground for unchecked antibiotic and opioid distribution (Moon et al., 2011). This dynamic reproduces cycles of dependency, harm, and inequity under the guise of “access.”

Philanthrocapitalism and the Gates Foundation: Benevolent Power or New Colonialism?

Parallel to corporate interests, philanthropic entities most notably the Bill & Melinda Gates Foundation exert profound influence over global health policy. Their funding and advocacy have undeniably driven progress in vaccine development and infectious disease control. However, critics argue that philanthrocapitalism distorts global health governance, privileging vertical, technocratic solutions over systemic strengthening of local health systems (McCoy et al., 2009).

The Gates Foundation’s outsized role in agenda-setting risks marginalizing LMIC voices and public sector autonomy, often turning recipient countries into implementers of externally driven programs rather than architects of their own health futures (Storeng, 2014). In AMR efforts, this can manifest as donor-driven surveillance and stewardship programs that lack sustainability or local ownership.

Conclusion: Whose Interests Are Served?

The silent pandemic of AMR is as much a crisis of power, equity, and governance as it is a scientific challenge. The opioid tragedy in the US, the unregulated antibiotic markets in LMICs, and the shaping of global health priorities by philanthropic billionaires illustrate a global health architecture deeply skewed by corporate and elite interests.

Profit, paternalism, and political influence dominate over protection, participation, and justice. Unless international regulatory frameworks hold Big Pharma accountable, foster genuine local empowerment, and confront the contradictions of philanthropic power, AMR will continue to thrive as a symptom of global inequity.

The question remains: Can global health innovation and investment become tools for equity rather than smokescreens for exploitation? This is the challenge and moral imperative of our time.

References

Belkhir, L. and Seguin, C. (2018) ‘Science and technology: Antibiotics production and the ethics of environmental dumping’, Global Bioethics, 29(1), pp. 42–56.

Centers for Disease Control and Prevention (CDC) (2023) Fentanyl Overdose Data. Available at: https://www.cdc.gov/opioids (Accessed: 25 June 2025).

Larsson, D.G.J. et al. (2018) ‘Effluent from drug manufacturing contains extremely high levels of antibiotics and bacteria resistant to those antibiotics’, Journal of Hazardous Materials, 354, pp. 131–137.

McCoy, D., Kembhavi, G., Patel, J. and Luintel, A. (2009) ‘The Bill & Melinda Gates Foundation’s grant-making programme for global health’, The Lancet, 373(9675), pp. 1645–1653.

Moon, S. et al. (2011) ‘A win–win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries’, Globalization and Health, 7(1), p. 39.

Okeke, I.N. et al. (2021) ‘Regulatory gaps and AMR policy inertia in Kenya’, PLOS Medicine, 18(4), e1003600.

Renwick, M., Brogan, D. and Mossialos, E. (2016) ‘A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics’, Journal of Antibiotics, 69(2), pp. 73–88.

Storeng, K.T. (2014) ‘The GAVI Alliance and the ‘Gates approach’ to health system strengthening’, Global Public Health, 9(8), pp. 865–879.

Van Zee, A. (2009) ‘The promotion and marketing of OxyContin: Commercial triumph, public health tragedy’, American Journal of Public Health, 99(2), pp. 221–227.

World Health Organization (WHO) (2024) Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report. Geneva: WHO. Available at: https://www.who.int (Accessed: 25 June 2025).